1例抗磷脂综合征合并HELLP综合征患者肾脏替代治疗期间的抗凝治疗分析和药学监护  

Analysis of Anticoagulant Therapy and Pharmaceutical Care for a Patient with Antiphospholipid Syndrome and HELLP Syndrome during Renal Replacement Therapy

作　　者：王斌霞 唐莲[2] 李兰 Wang Binxia;Tang Lian;Li Lan(Department of Pharmacy,Jingmen No.2 People’s Hospital,Hubei Jingmen 448000,China;Department of Pharmacy,Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital)

机构地区：[1]荆门市第二人民医院药学部,湖北荆门448000 [2]南京医科大学附属苏州医院药学部

出　　处：《中国药师》2022年第6期1040-1044,共5页China Pharmacist

基　　金：江苏省药学会医院药学科研项目(编号:A201914)。

摘　　要：临床药师参与1例抗磷脂综合征合并溶血性贫血、肝功能升高,血小板计数低综合征(HELLP综合征)患者的治疗过程,及时发现和解决抗凝药物治疗问题、消除患者治疗中的药物安全隐患,同时将抗凝领域的最新的循证证据资料和指南应用到临床实践中,在抗凝药物治疗方面提出优化建议,提供个体化药学服务。临床药师深入开展全程化药学监护,为优化多病共患患者的药物治疗结局发挥了重要作用。Clinical pharmacists participated in the anticoagulant therapy for one patient with antiphospholipid syndrome and HELLP syndrome. Clinical pharmacists timely discovered and solved the problem in the selection of anticoagulant drugs, and avoided the risk for medication safety in the treatment of patient. Meantime, clinical pharmacists provided the latest evidence of evidence-based data in the field of anticoagulation and clinical practice guidelines, optimized the anticoagulant therapy, and provided personalized pharmaceutical care. Clinical pharmacists can play an important role in optimizing the drug treatment for patients with multiple comorbidities by performing whole-process pharmaceutical care.

关 键 词：抗磷脂综合征 HELLP综合征 肾脏替代治疗 抗凝治疗 阿加曲班 磺达肝葵钠 药学监护 

分 类 号：R97[医药卫生—药品]